Company: AVCRF
Filing Date: 2025-06-16
Form Type: 20-F
Source: 0001641172-25-015266
Chunk: 22

Company: Avricore Health Inc.
Filing Date: 2025-06-16
Form: 20-F
Item: Item 6
Chunk 22
---
 the business of the
Company, will not receive any personal benefit from any party having business with the Company without the approval of the Board of Directors
of the Company and, during the term of the agreement and for a period of one year afterwards, will not compete with the Company or solicit
customers or employees of the Company.

The
Officers may terminate their respective agreements with the Company by giving thirty (30) days written notice to the Company. The Company
may waive such notice and, if it does so, such agreements will cease on the date the Company waives such notice. The Company may terminate
the agreements without notice or payment in lieu of notice for breach of the agreement. The Company may terminate any agreement at its
sole discretion and for any reason upon giving the Officer written notice of termination provided that the Company pays, in lieu of notice,
three (3) months fee severance. The Company may terminate any agreement without notice or payment in lieu of notice upon a change of
control of the holding company of the Officer or the death or permanent disability of the Officer. Upon termination of an agreement,
the Officer will promptly return all property. Each agreement may be subject to the acceptance by TSX Venture Exchange and a refusal
to do so shall not constitute a default of the Company.

  25  

6. C.3.
Board of Director Committees.

The
Company has an Audit Committee, which is governed by an Audit Committee Charter (filed as Exhibit hereto) and recommends to the Board
of Directors the engagement of the independent auditors of the Company and reviews with the independent auditors the scope and results
of the Company’s audits, the Company’s internal accounting controls, and the professional services furnished by the independent
auditors to the Company. The current members of the Audit Committee are: David Hall (Chairman), Robert Sindelar (Director) and Alan Arnstein
(Director). The Audit Committee met once during the year ended December 31, 2024 to discuss and recommend approval by the Board of the
Company’s audited financial statements. The interim financial statements and related Management Discussion and Analysis were approved
by joint consent resolution.

6. D.
Employees

As
of December 31, 2024, the Company employed 1 employee. The Company engaged the services of Chief Executive Officer, Chief Financial Officer
and Corporate Secretary, and Chief Technology Officer through consulting service contracts.

6. E.
Share Ownership

Table
No. 10 lists, as of the date of